Ipsen and Spirogen's SJG-136 shows encouraging results in the treatment of refractory solid tumours at ASCO
Ipsen (Euronext: IPN) and Spirogen Ltd. announced today that final results from a Phase I clinical trial of the DNA sequence recognizing minor groove binder SJG-136 sponsored by the US National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Ipsen were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago by Dr. Igor Puzanov from Vanderbilt-Ingram Cancer Center (Nashville, USA).
SJG-136 (SG2000/BN2629/NSC 694501) is a small molecule which spans six base pairs of DNA and is currently undergoing clinical development in refractory solid tumours and haematological malignancies under the CRADA with the NCI.
www.spirogen.com/20080602.pdf
-- ENDS --
Spirogen Ltd. is a pharmaceutical company pioneering the discovery and development of a unique class of low molecular weight, sequence-selective, DNA-interactive drugs designed to treat gene-mediated diseases. Spirogen has an extensive patent portfolio, including a number of granted patents, relating to its core technology. A number of the cases cover active PBD compounds, and their uses in medicine. The company was founded in March 2000. Spirogen has 10 employees split between laboratory and office facilities at new custom designed facilities at The School of Pharmacy (University of London) and the Cancer Institute (University College London).
www.spirogen.com
Leading in DNA Targeted Therapeutics
